TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 644-652

  Wong, Nathalie ^a,c   Yeo, Winnie ^a   Wong, Wai Lap ^a   Wong, Navy L Y ^a   Chan, Kathy Y Y ^a   Mo, Frankie K F ^a   Koh, Jane ^a   Chan, Stephan Lam ^a   Chan, Anthony T C ^a   Lai, Paul B S ^a   Ching, Arthur K K ^a   Tong, Joanna H M ^a   Ng, Ho Keung ^a   Johnson, Philip J ^b   To, Ka Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarker; Chemosensitization; Hepatocellular carcinoma; TOP2A

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MICROARRAY; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGE OF ONSET; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 58149280832     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23968     Document Type: Article

References (47)

1. Hong Kong Hospital Authority. Cancer incidence and mortality in Hong Kong 1999. Hong Kong Cancer Registry, Hong Kong, 2002.
2. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 1984;62: 163-82.
3. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangio-carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:1198-203.
4. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-8.
5. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988;15:1-31.
6. Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM. 4-Epidoxorubicin (Epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985;11:1535-40.
7. Yeo W, Mok TS, Zee B, Leung WT, Lau PBS, Lau WY, Koh J, Mo MKF, Yu S, Chan AT, Hui P, Ma B, et al. Phase III study of adriamy-cin versus cisplatin/interferon a-2b/adriamycin/ fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9:125-38.
10. Endicott J, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989;58:137-71.
11. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
12. Poon TC, Wong N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma-bioinformatic analysis of genomic data. Gastroenterology 2006;131:1262-70.
13. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001;85:697-704.
14. Guan XY, Fang Y, Sham JS, Kwong DL, Zhang Y, Liang Q, Li H, Zhou H, Trent JM. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000;29:110-16.
15. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Zhong S, Lau LW, Johnson PJ. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size and cirrhosis. Am J Pathol 1999;154:37-43.
16. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002;99:12963-8.
17. Heidenblad M, Lindgren D, Veltman JA, Jonson T, Mahlamaki EH, Gorunova L, van Kessel AG, Schoenmakers EF, Hoglund M. Microar-ray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene 2005;24:1794-801.
18. Wong N, Chan KY, Macgregor PF, Lai PB, Squire JA, Beheshti B, Albert M, Leung TW. Transcriptional profiling identifies gene expression changes associated with α-interferon resistance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 2005;11:1319-26.
19. Chan KY, Wong N, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, To KF, Johnson PJ. Transcriptional profiling on chromosome 19p indicated frequent down-regulation of ACP5 expression in hepatocellular carcinoma. Int J Cancer 2005;114:902-8.
20. Pang E, Wong N, Lai PB, To KF, Lau WY, Johnson PJ. Consistent chromosome 10 rearrangements in four newly established human hepatocellular carcinoma cell lines. Genes Chromosomes Cancer 2002;33:150-9.
21. World Health Organization. World Health Organization Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
22. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 2004;10: 3237-48.
23. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, et al. Gene expression profiling identifies clinically relevant subtypes ofprostate cancer. Proc Natl Acad Sci USA 2004;101:811-6.
24. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003;100:2532-7.
25. Staub E, Grone J, Mennerich D, Ropcke S, Klamann I, Hinzmann B, Castanos-Velez E, Mann B, Pilarsky C, Brummendorf T, Weber B, Buhr HJ, et al. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 2006;5:1-44.
26. Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, Elvin P, Cassidy A, Graham A, Spraggon C, Desille Y, Fourquet A, Nos C, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes-a study of 130 invasive ductal breast carcinomas. Cancer Res 2005;65:1376-83.
27. Varis A, Wolf M, Monni O, Vakkari M-L, Kokkola A, Moskaluk C, Frierson H, Jr, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002;62:2625-9.
28. Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J, Casey G. Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer 1997;20:354-62.
29. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
30. Stacey DW, Hitomi M, Chen G. Influence of cell cycle and oncogene activity upon topoisomerase IIα expression and drug toxicity. Mol Cell Biol 2000;20:9127-37.
31. Fritz P, Cabrera CM, Dippon J, Gerteis A, Simon W, Aulitzky WE, van der Kuip H. c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 2005;7:R374-R384.
32. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G. Expression of DNA topoisomerase IIα and topoisom-erase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999;5:2048-58.
33. Lazaris AC, Kavantzas NG, Zorzos HS, Tsavaris NV, Davaris PS. Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 2002;128:114-18.
34. Costa MJ, Hansen CL, Holden JA, Guinee D,Jr. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol 2000;19:248-57.
35. Paradis V, Bièche I, Dargère D, Laurendeau I, Laurent C, Sage PB, Degott C, Belghiti J, Vidaud M, Bedossa P. Molecular profiling of hepatocellular carcinomas (HCC) Using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003;163:733-11.
36. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98:15089-94.
37. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 2003;12:35-50.
38. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T, SHG AML, 96 Study Group.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005;128:324-32.
39. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006;100:152-9.
40. Henness S, Davey MW, Harvie RM, Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002;54:895-902.
41. Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N. Karyotypic imbalances and differential genes expression in the acquired doxorubicin resistance pheno-type of hepatocellular carcinoma cells. Lab Invest 2005;85:664-74.
42. Capranico G, Zagotto G, Palumbo M. Development of DNA topo-isomerase-related therapeutics: a short perspective of new challenges. Curr Med Chem Anticancer Agents 2004;4:335-45.
43. OkadaY,TosakaA,NimuraY,KikuchiA,YoshidaS,SuzukiM.Atyp-ical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001;272:141-8.
44. Asano T. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 1996;73:1373-80.
45. Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES. Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999;59:4618-24.
46. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
47. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093-108.